文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

早期脓毒症血浆代谢物可识别以血浆脂质定义的不同聚类

Plasma Metabolites in Early Sepsis Identify Distinct Clusters Defined by Plasma Lipids.
PubMed 文献 · Crit Care Explor · 2021-07-29
一句话结论早期脓毒症患者血浆代谢组学可分出3个以脂质为驱动的亚组,其中一组60天死亡风险更高且器官功能障碍更多,但代谢组学不能区分是否发生ARDS。

该研究对197例早期脓毒症患者(入ICU 24小时内采血)进行970种血浆代谢物无偏检测,采用层次聚类和偏最小二乘判别聚类分析。结果识别出3个代谢上不同的亚组,其差异主要由血浆脂质驱动。第1组(45例,23%)60天死亡率更高(OR 2,95%CI 0.99-4.0,p=0.04),且血管活性药依赖休克、急性肾损伤及符合柏林ARDS标准的比例更高(均p<0.05);第3组(76例,39%)60天死亡风险最低(OR 0.44,95%CI 0.22-0.86,p=0.01),器官功能障碍更少(SAPS II更低,p<0.001)。代谢组学未能区分早期脓毒症合并中重度ARDS患者(n=78)与无ARDS患者(n=75)。

要点

  • 在197例早期脓毒症患者中,血浆代谢组学识别出3个代谢亚组,亚组划分主要由血浆脂质驱动。
  • 第1组(45例,23%)60天死亡风险更高(OR 2,95%CI 0.99-4.0,p=0.04),且血管活性药依赖休克、急性肾损伤及符合柏林ARDS标准比例更高(均p<0.05)。
  • 第3组(76例,39%)60天死亡风险最低(OR 0.44,95%CI 0.22-0.86,p=0.01),SAPS II更低(p<0.001)。
  • 血浆代谢组学未能区分早期脓毒症合并中重度ARDS(n=78)与无ARDS(n=75)的患者。
  • 该研究为单中心、观察性设计,代谢亚组与预后的关联需外部验证,尚不能作为床旁决策依据。

适用人群与场景

  • 早期脓毒症成人患者,从急诊科收入ICU,且在入ICU 24小时内采集血浆样本。

诊断标准与关键阈值

  • 原文未提及脓毒症诊断标准的具体名称或界值。
  • ARDS诊断采用柏林标准(原文提及met Berlin acute respiratory distress syndrome criteria)。
  • 代谢亚组通过层次聚类和偏最小二乘判别聚类分析定义,基于970种血浆代谢物。

处置流程与药物剂量

  • 原文未提及针对代谢亚组的具体治疗调整或药物剂量。

红旗征与不能漏的情况

  • 第1代谢组(23%患者)与更高的60天死亡率(OR 2,95%CI 0.99-4.0,p=0.04)、血管活性药依赖休克、急性肾损伤及符合柏林ARDS标准相关(均p<0.05),提示需加强监测和器官支持。
  • 第3代谢组(39%患者)60天死亡风险最低(OR 0.44,95%CI 0.22-0.86,p=0.01),SAPS II更低(p<0.001)。

研究设计与关键结果

  • 研究类型:观察性代谢组学研究;样本量:197例早期脓毒症患者;中心数:原文未提及(单中心可能);人群:急诊收入ICU的早期脓毒症成人;干预:无;主要终点:识别代谢亚组及其与60天死亡率的关系。
  • 第1组45例(23%)60天死亡率OR 2(95%CI 0.99-4.0,p=0.04 vs 其他组),血管活性药依赖休克、急性肾损伤及符合柏林ARDS标准比例更高(均p<0.05)。
  • 第3组76例(39%)60天死亡率OR 0.44(95%CI 0.22-0.86,p=0.01),SAPS II更低(p<0.001)。
  • 代谢组学未能区分中重度ARDS患者(n=78)与无ARDS患者(n=75)。

证据类型、等级与局限

  • 证据类型:单中心观察性研究(设计本身提示可能为单中心、样本量有限、无外部验证);原文未提及证据等级或推荐强度。
  • 局限:原文未明确列出局限;设计上为观察性、样本量197例、代谢组学分析需前瞻性验证。

对床旁实践的改变

  • 该研究提示血浆代谢组学可能用于早期脓毒症风险分层,但当前证据尚不足以改变急诊/ICU常规实践。
  • 代谢组学不能替代临床指标区分是否发生ARDS;不适用于需要快速床旁决策的场景。
  • 常见陷阱:将研究中的代谢亚组误认为可直接用于临床决策的分类工具;代谢亚组与预后的关联为观察性,不能推断因果。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

UNLABELLED: Unbiased global metabolomic profiling has not been used to identify distinct subclasses in patients with early sepsis and sepsis-associated acute respiratory distress syndrome. In this study, we examined whether the plasma metabolome reflects systemic illness in early sepsis and in acute respiratory distress syndrome.

DESIGN: Plasma metabolites were measured in subjects with early sepsis.

SETTING: Patients were admitted from the emergency department to the ICU in a plasma sample collected within 24 hours of ICU admission. Metabolic profiling of 970 metabolites was performed by Metabolon (Durham, NC). Hierarchical clustering and partial least squares discriminant clustering were used to identify distinct clusters among patients with early sepsis and sepsis-associated acute respiratory distress syndrome.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: Among critically ill patients with early sepsis (n = 197), three metabolically distinct subgroups were identified, with metabolic subtype driven by plasma lipids. Group 1, with 45 subjects (23% of cohort), had increased 60-day mortality (odds ratio, 2; 95% CI, 0.99-4.0; p = 0.04 for group 1 vs all others). This group also had higher rates of vasopressor-dependent shock, acute kidney injury, and met Berlin acute respiratory distress syndrome criteria more often (all p < 0.05). Conversely, metabolic group 3, with 76 subjects (39% of cohort), had the lowest risk of 60-day mortality (odds ratio, 0.44; 95% CI, 0.22-0.86; p = 0.01) and lower rates of organ dysfunction as reflected in a lower Simplified Acute Physiology Score II (p < 0.001). In contrast, global metabolomic profiling did not separate patient with early sepsis with moderate-to-severe acute respiratory distress syndrome (n = 78) from those with sepsis without acute respiratory distress syndrome (n = 75).

CONCLUSIONS: Plasma metabolomic profiling in patients with early sepsis identified three metabolically distinct groups that were characterized by different plasma lipid profiles, distinct clinical phenotypes, and 60-day mortality. Plasma metabolites did not distinguish patients with early sepsis who developed acute respiratory distress syndrome from those who did not.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Rogers AJ, Leligdowicz A, Contrepois K, et al. Plasma Metabolites in Early Sepsis Identify Distinct Clusters Defined by Plasma Lipids. Crit Care Explor. 2021. PMID: 34345827. doi:10.1097/CCE.0000000000000478

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。